ADVERTISEMENT
Enzalutamide Added to Testosterone Suppression Provides OS Benefit in Metastatic Hormone–Sensitive Prostate Cancer
The addition of enzalutamide to testosterone suppression was found to provide a clinically meaningful overall survival (OS) benefit over a conventional non-steroidal anti-androgen for patients with metastatic hormone-sensitive prostate cancer, according to follow-up analysis of the phase 3 ENZAMET trial presented at the 2022 ASCO Annual Meeting.
“The first planned interim analysis of ENZAMET, with 243 deaths after a median follow-up of 34 months, revealed a clinically meaningful overall survival benefit in [metastatic hormone–sensitive prostate cancer] with the addition of enzalutamide to standard of care,” wrote Ian Davis, MD, Eastern Health Clinical School, Monash University, Box Hill, Australia, and collagues.
This follow-up analysis provides updated OS results from the prespecified analysis.
The ENZAMET trial randomized patients with metastatic hormone–sensitive prostate cancer to receive testosterone suppression with either a conventional non-steroidal anti-androgen or enzalutamide. This analysis was planned to occur after 470 deaths.
The median follow-up was 68 months and the data cut-off date was January 19, 2022. Patients were stratified based on age, volume of disease, and planned use of concurrent docetaxel as assigned by the treating physician.
Compared to the non-steroidal anti-androgen, there was a clinically meaningful improvement in OS for the combined overall cohort with enzalutamide added to testosterone suppression. The 5-year OS with enzalutamide was 67% vs 57% with the non-steroidal anti-androgen. This benefit was shown at the additional 3 years of follow-up.
Dr Davis and colleagues noted that this benefit was more pronounced in patients with low-volume disease (80% with enzalutamide vs 66% with control) and those with M1 high volume (55% vs 51%, respectively).
Source:
Davis ID, Martin AJ, Zielinski RR, et al. Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). Presented at: 2022 ASCO Annual Meeting; June 3-7, 2022. Chicago, IL. Abstract LBA5004.
